Trials / Completed
CompletedNCT03444883
Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD
A Multicenter, Randomized, Parallel, Double Blind, Placebo-controlled Phase III Study to Evaluate Safety and Efficacy of Ilaprazole 20mg in Patients With Non-erosive Reflux Disease(NERD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 277 (actual)
- Sponsor
- Il-Yang Pharm. Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Ilaprazole 20 mg in patients with non-erosive reflux disease. This study intends to demonstrate the clinical superiority of Ilaprazole 20 mg to placebo administered once daily for 4 weeks.
Detailed description
This study is multicenter, randomized, parallel, double blind, placebo-controlled phase III study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ilaprazole | 10mgx2 tablet once daily for weeks |
Timeline
- Start date
- 2018-10-31
- Primary completion
- 2020-02-25
- Completion
- 2020-02-25
- First posted
- 2018-02-23
- Last updated
- 2021-01-05
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03444883. Inclusion in this directory is not an endorsement.